ENVARSUS 0.75mg (Tacrolimus Tablet) 0.75mg

Envarsus 0.75mg is a prolonged-release tablet containing tacrolimus, an immunosuppressant used to prevent organ transplant rejection. This formulation is designed for steady drug release. Envarsus 0.75mg tablet is prescribed for adults and children.

Strength

0.75mg

Pack Size

30s

Storage

Ambient

Manufacturer / TM Owner

Chiesi

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Envarsus 0.75mg is primarily used to prevent the body from rejecting a transplanted kidney or liver. It belongs to a class of medications called immunosuppressants, which help reduce the activity of the immune system. This medication is often prescribed alongside other immunosuppressants to support long-term transplant success.

Side Effects

Envarsus 0.75mg works by lowering the immune system's response to help prevent organ rejection after a transplant. Patients may notice improved transplant function over time as the medication takes effect. Regular blood tests are typically required to monitor drug levels and overall health.

Precautions & Warnings

Keep Envarsus 0.75mg tablets in their original packaging until use to protect from moisture. Store at room temperature away from direct light and heat. Always handle with dry hands and avoid splitting or crushing the tablets. Do not take if the packaging is damaged or the tablets appear altered.

Avoid Interactions

Certain medications, including some antibiotics, antifungals, and herbal supplements, may interact with Envarsus 0.75mg. Grapefruit and grapefruit juice can affect how the body processes tacrolimus. Always inform your healthcare provider about all medications and supplements you are taking to avoid potential interactions.

Frequently Asked Questions

Envarsus 0.75mg is used to prevent organ transplant rejection in adults and children.

Store at room temperature, away from moisture and direct light, in the original packaging.

No, the tablets should not be split or crushed as this may affect the medication’s release profile.

Food can influence absorption; it is typically taken consistently with or without food as directed by a healthcare provider.

Grapefruit and grapefruit juice may interact with tacrolimus; avoid consuming them unless advised otherwise.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.